Japan Pharma: Core Coverage Investment Thesis and Valuations (II/III)
Takeda Pharmaceutical (4502 JP), Astellas Pharma (4503 JP), Daiichi Sankyo (4568 JP), Eisai Co Ltd (4523 JP), Otsuka Holdings (4578 JP), Chugai...
425 Views
Japan Pharma: Core Coverage Investment Thesis and Valuations (I/III)
Takeda Pharmaceutical (4502 JP), Astellas Pharma (4503 JP), Daiichi Sankyo (4568 JP), Eisai Co Ltd (4523 JP), Otsuka Holdings (4578 JP), Chugai...
449 Views
Takeda Pharmaceutical: Looking Forward To Pending Approvals and Late Stage Pipeline in FY27
Takeda Pharmaceutical reported lower FY26 revenue due to generic erosion, but expects growth in FY27 driven by new launches and core brands, with...
146 Views
Sumitomo Pharma (4506 JP): America Drives FY26, To Be Continued in FY27, Enzomenib in Pivotal Phase
Sumitomo Pharma sees strong revenue growth in FY26 driven by North America. Momentum to continue in FY27. Profits to see some downside on R&D cost...
132 Views
Japan Pharma - FY17e Earnings Preview (I)
Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...
272 Views